InFlectis BioScience
InFlectis BioScience
InFlectis is developing first-in-class therapies for neuromuscular diseases. We are in clinical development with an orally-available small molecule that has the potential to extend lives or improve the quality-of-life for people suffering from ALS and CMT, a rare and progessive hereditary nerve condition.
View More Biotech Web Sites